PT-141

Bremelanotide

Melanocortin receptor agonist · Sexual response research

A cyclic heptapeptide analog of α-MSH acting at central melanocortin receptors. Approved as Vyleesi® for hypoactive sexual desire disorder; widely studied in melanocortin pathway research.

For laboratory research use only. Not for human or animal consumption, not a drug, food, cosmetic, or supplement. By adding to cart, the researcher affirms compliance with all applicable regulations.

Vial size

Research price

$69

SKU ABL-PT1-10

Ships cold-chain · Lot ABL-PT1-2601 · Checkout secured by Waave

Specifications

CAS number

189691-06-3

Molecular formula

C50H68N14O10

Molecular weight

1025.18 g/mol

Sequence

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Purity (HPLC)

≥99%

Appearance

White to off-white lyophilized powder

Storage

Store lyophilized at 2–8 °C, protected from light and moisture

Reconstitution

Reconstitute in sterile diluent appropriate to researcher protocol

Latest lot

ABL-PT1-2601

PT-141, known generically as Bremelanotide, is a cyclic heptapeptide derivative of α-melanocyte stimulating hormone. It acts as a non-selective agonist at melanocortin receptors with preferential activity at MC3R and MC4R in published pharmacology literature.

Originally investigated as a sunless tanning agent, subsequent research identified central effects on sexual motivation and arousal in preclinical models and clinical trials. The molecule is FDA-approved as Vyleesi® for the treatment of premenopausal hypoactive sexual desire disorder.

Supplied as a research-grade reference peptide for investigation of central melanocortin signaling. Not supplied for therapeutic use.